World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
108
Citations
76166
World Ranking
5865
National Ranking
169

Stéphane Oudard publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Stéphane Oudard sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 821 publications — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Stéphane Oudard D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Stéphane Oudard sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 108 D-Index — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Stéphane Oudard is affiliated with Hôpital Européen Georges-Pompidou in France. Their research primarily focuses on medicine, with particular emphasis on pulmonary and respiratory medicine, oncology, surgery, cancer research, and molecular biology.

The scientist has significant contributions in key topics including:

  • Renal cell carcinoma treatment
  • Cancer immunotherapy and biomarkers
  • Prostate cancer treatment and research
  • Bladder and urothelial cancer treatments
  • Cancer genomics and diagnostics
  • Renal and related cancers
  • Radiopharmaceutical chemistry and applications

Stéphane Oudard's recent papers include:

  • Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma (2021) published in New England Journal of Medicine
  • Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer (2022) published in Immunity
  • Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial (2021) published in The Lancet Oncology
  • ctDNA guiding adjuvant immunotherapy in urothelial carcinoma (2021) published in Nature
  • Bone health in cancer: ESMO Clinical Practice Guidelines (2020) published in Annals of Oncology

The frequent co-authors with whom Stéphane Oudard has collaborated include Brigitte Laguerre, Gwénaëlle Gravis, Yann Vano, Philippe Barthélémy, and Laurence Albigès.

The venues where the scientist has published most frequently are:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • The Lancet Oncology
  • European Journal of Cancer
  • European Urology

Best Publications

  • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

    Robert J. Motzer;Thomas E. Hutson;Piotr Tomczak;M. Dror Michaelson

  • Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

    Ian F. Tannock;Ronald de Wit;William R. Berry;Jozsef Horti

  • Sorafenib in advanced clear-cell renal-cell carcinoma.

    Bernard Escudier;Tim Eisen;Walter M. Stadler;Cezary Szczylik

  • Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

    Johann Sebastian De Bono;Stephane Oudard;Mustafa Ozguroglu;Steinbjørn Hansen

  • Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

    Robert J Motzer;Bernard Escudier;Stéphane Oudard;Thomas E Hutson

  • Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;Thomas E. Hutson;Piotr Tomczak;M. Dror Michaelson

  • Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

    Thomas Powles;Ignacio Durán;Michiel S van der Heijden;Yohann Loriot

  • Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

    Robert J. Motzer;Bernard Escudier;Stephane Oudard;Thomas E. Hutson

  • Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

    Bernard Escudier;Tim Eisen;Walter M. Stadler;Cezary Szczylik

  • Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

    Matthew R Smith;Fred Saad;Simon Chowdhury;Stéphane Oudard

  • Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

    Arnaud Méjean;Alain Ravaud;Simon Thezenas;Sandra Colas

  • Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

    Robert J Motzer;Bernard Escudier;Piotr Tomczak;Thomas E Hutson

  • Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

    Gwenaelle Gravis;Karim Fizazi;Florence Joly;Stéphane Oudard

  • Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

    Robert J. Motzer;Brian I. Rini;David F. McDermott;Osvaldo Arén Frontera

  • Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

    Martin E Gore;Cezary Szczylik;Camillo Porta;Sergio Bracarda

  • PD-1–Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer

    Cécile Badoual;Stéphane Hans;Nathalie Merillon;Cordélia Van Ryswick

  • Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.

    Toni K. Choueiri;Piotr Tomczak;Se Hoon Park;Balaji Venugopal

  • Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma

    Toni K. Choueiri;Anne Plantade;Paul Elson;Sylvie Negrier

  • Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.

    Gwenaelle Gravis;Jean-Marie Boher;Florence Joly;Michel Soulié

  • Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal

    Thomas J. Mitchell;Samra Turajlic;Andrew Rowan;David Nicol

Frequent Co-Authors

Bernard Escudier
Bernard Escudier Institut Gustave Roussy
Karim Fizazi
Karim Fizazi University of Paris-Saclay
Alain Ravaud
Alain Ravaud University of Bordeaux
Fred Saad
Fred Saad University of Montreal
Christine Chevreau
Christine Chevreau DuPont (United States)
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Laurence Albiges
Laurence Albiges Institut Gustave Roussy
Camillo Porta
Camillo Porta University of Bari Aldo Moro
Eric J. Small
Eric J. Small University of California, San Francisco
Matthew R. Smith
Matthew R. Smith Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are considering a medical career, there are several online degree options and specialized pathways to explore beyond a traditional MD program. For those interested in advanced nursing roles, pursuing a cheapest dnp programs can be a cost-effective way to earn a Doctor of Nursing Practice and advance into leadership or clinical expert roles.

Pharmacists are in high demand, and accredited pharmd online programs offer flexibility for working professionals or those balancing other commitments while earning their Doctor of Pharmacy degree.

Interested in healthcare administration or data management? You can start a promising career by enrolling in online rhit degree programs, which prepare you for the Registered Health Information Technician (RHIT) certification and open doors to roles centered on health data systems.

For those seeking a quicker path into healthcare, understanding the average cost of medical billing and coding program can help you start a career in medical billing and coding, a vital area with growing job prospects and remote work flexibility.

Best Scientists Citing Stéphane Oudard

Trending Scientists

Recently Published Articles